QR-kod

Dapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 study

AimsTo evaluate the efficacy and safety of dapagliflozin plus pioglitazone versus comparators on metabolic control and hepatic steatosis in adults with type 2 diabetes mellitus (T2DM), with or without metabolic dysfunction-associated steatotic liver disease (MASLD).MethodsWe conducted a systematic r...

Full beskrivning

Sparad:
Huvudupphov: Shashank Joshi, Shambo Samrat Samajdar, Arvind Gupta, Mithun Bhartia, Sailesh Lodha, Supratik Bhattacharyya, Krishna Seshadri, Lakshmi Nagendra, A. G. Unnikrishnan, Dakshata Padhye, Lakshmi Nalini Kopalle, Ashok Kumar Das, Om Lakhani, Jothydev Kesavadev, Ameya Joshi, Sambit Das, Smriti Gadia, Thamburaj Anthuvan
Materialtyp: Artigo
Språk:Inglês
Utgiven: Frontiers Media S.A. 2026-07-01
Serie:Frontiers in Clinical Diabetes and Healthcare
Ämnen:
combination therapy
dapagliflozin
MASLD
NAFLD
pioglitazone
SRMA
Länkar:https://www.frontiersin.org/articles/10.3389/fcdhc.2026.1733995/full
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk